Study of Depression-Ketamine-Brain Function

Status Terminated

Clinical Trial Summary

Targeting the glutamatergic system to treat depression is a new and promising strategy based on studies at the molecular, synaptic, and neuronal level but also on results of studies conducted in animal models and first clinical studies involving depressed patients.Ketamine has been proposed as a novel approach to induce rapid antidepressant response. In this pilot project the investigators aim to introduce this novel and promising approach into clinical practice. Besides the assessment of clinical efficacy, the investigators will put a special emphasis on the assessment of ketamine-associated effects on brain function using fMRI and cognitive testing.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01135758
Study type	Interventional
Source	University Hospital, Geneva
Contact
Status	Terminated
Phase	Phase 2
Start date	June 2010
Completion date	September 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03062150` - Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression	N/A
Completed	`NCT04352101` - Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits	Phase 4
Completed	`NCT02855918` - Blood Biomarkers in Suicidal Behaviour	N/A
Recruiting	`NCT03039387` - Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients	N/A
Recruiting	`NCT02213016` - Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients	Phase 4
Completed	`NCT01683539` - Understanding How Cognitive Remediation Works	N/A
Completed	`NCT01636791` - CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care	Phase 3
Recruiting	`NCT02237937` - Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene	Phase 4
Completed	`NCT01201148` - Open Pilot Trial of TES for Depression	Phase 2
Completed	`NCT00953108` - Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients	Phase 3
Terminated	`NCT01244711` - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines	Phase 4
Terminated	`NCT00695552` - The Effect of Exercise on Depressive Symptoms in Unmedicated Patients	N/A
Completed	`NCT00806143` - Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression	Phase 4
Completed	`NCT00711737` - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months	N/A
Completed	`NCT00482482` - Yoga in Unipolar and Bipolar Disorders	N/A
Completed	`NCT00466323` - The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.	N/A
Completed	`NCT00532480` - Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine	Phase 4
Completed	`NCT00616759` - The Effect on Cognition of Terminating ECT Induced Seizures With Propofol	N/A
Recruiting	`NCT00209807` - Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder	Phase 4
Completed	`NCT00167310` - Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation	Phase 2